Trial Profile
A Phase IIa, randomized, two-arm parallel-group, placebo-controlled, double-blind, multi-centre trial to evaluate the safety, tolerability, anti-inflammatory and cardio-protective effects after intravenous and oral administration of KAND567 in ST-elevation myocardial infarction (STEMI) patients undergoing percutaneous coronary intervention
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 14 Feb 2024
Price :
$35
*
At a glance
- Drugs KAND-567 (Primary) ; KAND-567 (Primary)
- Indications Cardiovascular disorders; Myocardial infarction
- Focus Adverse reactions
- Acronyms FRACTAL
- Sponsors Kancera
- 06 Feb 2024 According to a Kancera media release, additional findings are planned to be reported during the second quarter 2024.
- 06 Feb 2024 According to a Kancera media release, signals of cardio-protective effects seen in the FRACTAL study are very encouraging, and are established markers for the anticipated efficacy endpoints in upcoming phase IIb/III studies.
- 06 Feb 2024 Results presented in a Kancera Media Release.